

RECEIVED  
CENTRAL FAX CENTER

JUN 18 2007



Vertex Pharmaceuticals Incorporated  
130 Waverly Street • Cambridge, MA 02139-4242  
Tel. 617.444.6100 • Fax 617.444.6483  
<http://www.vrtx.com>

---

## FAX TRANSMISSION

To	USPTO – Mail Stop Amendment 571-273-8300
Examiner	Rebecca L. Anderson
Group Art Unit	1626
From	Daniel A. Pearson
Date	June 18, 2007
Application No.	10/626,356
Attorney Docket No.	VPI/00-122 DIV2 US
Total Pages	25

### Message or Comment

If any problems occur with this fax transmittal, please call (617) 444-7517  
Immediately.

RECEIVED  
CENTRAL FAX CENTER

JUN 18 2007


Attorney Docket No.: VPI/00-122 DIV2 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/626,356  
Confirmation No.: 1551  
Filing Date: July 24, 2003  
Examiner: Rebecca L. Anderson  
Group Art Unit: 1626  
Applicants: Michael Hale et al.  
For: ISOXAZOLE COMPOSTIONS USEFUL AS INHIBITORS OF ERK

**Certificate of Facsimile Transmission Under 37 CFR §1.8**

I hereby certify that this correspondence and any documents referred to as attached hereto, are being facsimile transmitted to the United States Patent and Trademark Office on June 18, 2007.

  
Lauren M. DeVincenzo

June 18, 2007  
Cambridge, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Sir:

Transmitted herewith: ☒ an Amendment and Reply to Office Action; ☐ a Petition for Extension of Time; ☐ a Declaration; ☐ a Power of Attorney; ☐ a copy of a Notice to File Missing Parts; ☐ a Response to Notice to File Missing Parts; ☐ a Supplemental Declaration; ☐ an Associate Power of Attorney; ☐ a substitute Specification; ☐ formal drawings; ☐ Notice of Appeal; ☐ Appeal Brief; ☐ Petition for Revival; to be filed in the above-identified patent application.

RECEIVED  
CENTRAL FAX CENTER

JUN 18 2007


Applicants: Michael Hale et al.  
Application No.: 10/626,356FEE FOR ADDITIONAL CLAIMS

- ☒ A fee for additional claims is not required.
- ☐ A fee for additional claims is required.
- ☐ Please charge \$\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.
- ☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

- ☐ Please charge \$\_\_\_\_\_ to Deposit Account No. 50-0725 in payment of the \_\_\_\_\_ (37 C.F.R. § \_\_\_\_\_).

Respectfully submitted,



Daniel A. Pearson Reg. No. 58,053  
Agent for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6790  
Fax: (617) 444-6483

RECEIVED  
CENTRAL FAX CENTER

JUN 18 2007

Attorney Docket No.: VPI/00-122 DIV2 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/626,356  
Confirmation No.: 1551  
Filing Date: July 24, 2003  
Examiner: Rebecca L. Anderson  
Group Art Unit: 1626  
Applicants: Michael Hale et al.  
For: ISOXAZOLE COMPOSTIONS USEFUL AS INHIBITORS OF ERK

**Certificate of Facsimile Transmission Under 37 CFR §1.8**

I hereby certify that this correspondence and any documents referred to as attached hereto are being facsimile transmitted to the United States Patent and Trademark Office on June 18, 2007.

  
Lauren M. DeVincenzo

June 18, 2007  
Cambridge, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Sir:

Transmitted herewith: ☒ an Amendment and Reply to Office Action; ☐ a Petition for Extension of Time; ☐ a Declaration; ☐ a Power of Attorney; ☐ a copy of a Notice to File Missing Parts; ☐ a Response to Notice to File Missing Parts; ☐ a Supplemental Declaration; ☐ an Associate Power of Attorney; ☐ a substitute Specification; ☐ formal drawings; ☐ Notice of Appeal; ☐ Appeal Brief; ☐ Petition for Revival; to be filed in the above-identified patent application.

RECEIVED  
CENTRAL FAX CENTER

JUN 18 2007


Applicants: Michael Hale et al.  
Application No.: 10/626,356FEE FOR ADDITIONAL CLAIMS

- ☒ A fee for additional claims is not required.
- ☐ A fee for additional claims is required.
- ☐ Please charge \$\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.
- ☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

- ☐ Please charge \$\_\_\_\_\_ to Deposit Account No. 50-0725 in payment of the \_\_\_\_\_ (37 C.F.R. § \_\_\_\_\_).

Respectfully submitted,



Daniel A. Pearson Reg. No. 58,053  
Agent for Applicants  
c/c Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6790  
Fax: (617) 444-6483

RECEIVED  
CENTRAL FAX CENTER  
JUN 18 2007

Attorney Docket No. VPI/00-122 DIV2 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/626,356  
Confirmation No.: 1551  
Filing Date: July 24, 2003  
Examiner: Rebecca L. Anderson  
Group Art Unit: 1626  
Applicants: Michael Hale et al.  
For: ISOXAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF ERK

June 18, 2007  
Cambridge, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT AND REPLY TO OFFICE ACTION

Sir:

This is in response to the March 16, 2007 Office Action in the above-identified application. A response is due June 16, 2006. Accordingly, this reply is timely filed.<sup>1</sup>

Amendments to the claims begin on page 2 of this Reply.

Remarks begin on 18 of this Reply.

<sup>1</sup> The Reply was due June 16, 2007, which was a Saturday. Pursuant to 37 C.F.R. § 1.7(a), the Reply may be filed on the next succeeding business day.